INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Corporate insider
KW

Kozarich John W

DirectorCIK 0001223000

EDGAR filingsOpen in network
Disclosed transactions34
Buys / sells0 / 28
Max Insider Score15
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
2
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Grant or award
A—
836 sh
Jun 5, 2026Jun 9, 2026
traded Jun 5, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    LIGAND PHARMACEUTICALS INCDirector · Nov 5, 2025
2
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Grant or award
A
—
2,938 sh
Jun 5, 2026
Jun 9, 2026
traded Jun 5, 2026
+4d
SEC FORM 4

Evidence

6
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$103K
459 sh
May 12, 2026May 14, 2026
traded May 12, 2026
+2dSEC FORM 4

Evidence

13
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$18K
80 sh
May 1, 2026May 14, 2026
traded May 1, 2026
+13dSEC FORM 4

Evidence

13
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$38K
165 sh
May 1, 2026May 14, 2026
traded May 1, 2026
+13dSEC FORM 4

Evidence

13
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$24K
105 sh
May 1, 2026May 14, 2026
traded May 1, 2026
+13dSEC FORM 4

Evidence

13
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$27K
116 sh
May 1, 2026May 14, 2026
traded May 1, 2026
+13dSEC FORM 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M$109K
1,575 sh
May 13, 2026May 14, 2026
traded May 13, 2026
+1dSEC FORM 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M$32K
459 sh
May 12, 2026May 14, 2026
traded May 12, 2026
+2dSEC FORM 4

Evidence

13
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$230
1 sh
May 1, 2026May 14, 2026
traded May 1, 2026
+13dSEC FORM 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M—
1,575 sh
May 13, 2026May 14, 2026
traded May 13, 2026
+1dSEC FORM 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M—
459 sh
May 12, 2026May 14, 2026
traded May 12, 2026
+2dSEC FORM 4

Evidence

9
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$352K
1,575 sh
May 13, 2026May 14, 2026
traded May 13, 2026
+1dSEC FORM 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$4,499
23 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$192
1 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$7,449
39 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$4,535
23 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

1
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$75K
381 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$8,850
46 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$3,918
21 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$17K
91 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$19K
102 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$39K
207 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

6
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$6,000
30 sh
Dec 1, 2025Dec 3, 2025
traded Dec 1, 2025
+2dSEC FORM 4

Evidence

6
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$4,582
23 sh
Dec 1, 2025Dec 3, 2025
traded Dec 1, 2025
+2dSEC FORM 4

Evidence

6
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$18K
92 sh
Dec 1, 2025Dec 3, 2025
traded Dec 1, 2025
+2dSEC FORM 4

Evidence

6
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$785
4 sh
Dec 1, 2025Dec 3, 2025
traded Dec 1, 2025
+2dSEC FORM 4

Evidence

6
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$9,203
47 sh
Dec 1, 2025Dec 3, 2025
traded Dec 1, 2025
+2dSEC FORM 4

Evidence

6
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$35K
179 sh
Dec 1, 2025Dec 3, 2025
traded Dec 1, 2025
+2dSEC FORM 4

Evidence

6
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$18K
92 sh
Dec 1, 2025Dec 3, 2025
traded Dec 1, 2025
+2dSEC FORM 4

Evidence

15
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$24K
127 sh
Nov 3, 2025Nov 5, 2025
traded Nov 3, 2025
+2dSEC FORM 4

Evidence

15
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$40K
207 sh
Nov 3, 2025Nov 5, 2025
traded Nov 3, 2025
+2dSEC FORM 4

Evidence

15
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$9,323
49 sh
Nov 3, 2025Nov 5, 2025
traded Nov 3, 2025
+2dSEC FORM 4

Evidence

15
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$16K
84 sh
Nov 3, 2025Nov 5, 2025
traded Nov 3, 2025
+2dSEC FORM 4

Evidence